<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39403934</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Neutralizing activity of anti-SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e182919</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI182919</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellusci</LastName><ForeName>Lorenza</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Golding</LastName><ForeName>Hana</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Surender</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="Y">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical practice</Keyword><Keyword MajorTopicYN="N">Immunoglobulins</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Infectious disease</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> The authors have declared that no conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39403934</ArticleId><ArticleId IdType="pmc">PMC11473157</ArticleId><ArticleId IdType="doi">10.1172/JCI182919</ArticleId><ArticleId IdType="pii">182919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Imai M, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2022;385(8):683–694.</Citation><ArticleIdList><ArticleId IdType="pubmed">34407342</ArticleId></ArticleIdList></Reference><Reference><Citation>Karbiener M, et al. Highly potent SARS-CoV-2 neutralization by intravenous immunoglobulins manufactured from post-COVID-19 and COVID-19-vaccinated plasma donations. J Infect Dis. 2021;224(10):1707–1711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499975</ArticleId><ArticleId IdType="pubmed">34543421</ArticleId></ArticleIdList></Reference><Reference><Citation> CDC. 2022-2023 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations).  https://covid.cdc.gov/covid-data-tracker/# nationwide-blood-donor-seroprevalence-2022 Accessed September 6, 2024.</Citation></Reference><Reference><Citation>Awasthi M, et al. Severe acute respiratory syndrome Coronavirus 2 hyperimmune intravenous human immunoglobulins neutralizes omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for treatment of Coronavirus disease 2019. Clin Infect Dis. 2022;76(3):e503–e506. doi: 10.1093/cid/ciac642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac642</ArticleId><ArticleId IdType="pmc">PMC9384659</ArticleId><ArticleId IdType="pubmed">35925647</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsoussi WB, et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature. 2023;617(7961):592–598. doi: 10.1038/s41586-023-06025-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06025-4</ArticleId><ArticleId IdType="pubmed">37011668</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JS, et al. Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front Immunol. 2022;13:1033651. doi: 10.3389/fimmu.2022.1033651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1033651</ArticleId><ArticleId IdType="pmc">PMC9932260</ArticleId><ArticleId IdType="pubmed">36818469</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>